Stingeni Luca, Malara Giovanna, Conti Andrea, Di Costanzo Luisa, Carrera Carlo Giovanni, Burlando Martina, Malagoli Piergiorgio, Musumeci Maria Letizia, Bardazzi Federico, Brazzelli Valeria, Amerio Paolo, De Simone Clara, Trevisini Sara, Balato Anna, Megna Matteo, Loconsole Francesco, De Felice Catia, Bartezaghi Marta, Rausa Alice, Aloisi Elisabetta, Orsenigo Roberto, Costanzo Antonio
Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy.
Dermatology Unit, Hospital "Bianchi Melacrino Morelli", Reggio Calabria, Italy.
Clin Cosmet Investig Dermatol. 2023 Jan 5;16:27-38. doi: 10.2147/CCID.S378135. eCollection 2023.
Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.
The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.
Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; <0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; =0.0779) and 24 (83.2% vs 79.7%; =0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (-10.9 vs -8.1, respectively, in females vs males; =0.0004).
In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.
银屑病是一种常见的全身性炎症性疾病，在生活质量（QoL）和治疗结果方面存在性别差异。这项来自3b期SUPREME研究的事后分析探讨了中度至重度银屑病患者在患者特征方面的性别差异，以及300mg司库奇尤单抗对银屑病面积和严重程度指数（PASI）75/90/100的疗效，以及在第24周时使用皮肤病生活质量指数（DLQI）对生活质量的影响。
采用无反应者插补法计算达到PASI 75/90/100的患者比例。使用逻辑回归模型分析队列之间的差异。使用Wilcoxon检验计算DLQI相对于基线的平均变化。
在433例患者中（男性：71.6%），女性在基线时的DLQI高于男性（13.1对9.5；<0.0001）。在第16周（80.7%对78.1%；P = 0.0779）和第24周（83.2%对79.7%；P = 0.0319），男性对PASI 90的反应略高于女性。在第24周，PASI 100/75反应的性别差异未观察到。在第24周时，两性使用司库奇尤单抗后DLQI均有改善（女性为-10.9，男性为-8.1；P = 0.0004）。
总之，无论性别如何，司库奇尤单抗在治疗银屑病方面均有效。
